Search
Back 

2018 Announcements

2018 Announcements

July 19, 2018

The Digital Health and Personal Connected Health Minisymposium was held at the NRG Oncology Seminannual Meeting on July 12th. This session reviewed the ins-and-outs of digital health and the technology that is currently being used to improve the way we deliver cancer care.  The recording of this session is now available here.

June 25, 2018

4th of July closures for Operations, SDMCs, Biospecimen Banks, Serum Bank, and McKesson's Clinical Research Services. Read more

June 25, 2018

NRG Oncology’s GOG-0218 Trial Leads to FDA Approval of Chemotherapy with Bevacizumab for Women with Ovarian Cancer Following Initial Surgery

The U.S. Food and Drug Administration (FDA) recently approved the use of bevacizumab (Avastin®) in combination with carboplatin and paclitaxel followed by Avastin as a single agent, as a treatment for women with advanced stage III or IV ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection. The FDA approval stems from the results of the double blind, placebo-controlled, phase 3 NRG Oncology trial GOG-0218, which revealed the addition of bevacizumab improved progression-free survival (PFS) for women when compared to chemotherapy alone. GOG-0218 was conducted by the Gynecologic Oncology Group (GOG, now part of NRG Oncology) and sponsored by the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) under its Cooperative Research and Development Agreement with Genentech, a member of the Roche Group, for bevacizumab. Read more

June 18, 2018

An Important Word from Quality Assurance About Protocol Amendments
In order to avoid problems at audit and at the time of patient enrollments, site staff must more closely monitor the NRG Oncology Weekly Broadcast for protocol amendments.  Amendments are announced in the weekly (typically Monday) broadcast under the heading, Protocol Activity, or sometimes, they are announced during the week in a separate broadcast.  Regardless, the location/website where the amendment is posted is included in the announcement. We understand some staff have problems receiving the e-mail broadcasts; so please spread the word that broadcasts are posted to the NRG Oncology website under the News tab and can be monitored from there.

May 21, 2018

Memorial Day closures for Operations, SDMCs, Biospecimen Banks, Serum Bank, and McKesson. Read more

May 7, 2018
Project Team Member Application – Rogaratinib

Applicants, please submit the form to the NRG protocol development office by COB Friday, May 18, 2018. NRG Oncology will submit the application to CTEP by the deadline of May 25, 2018.


April 4, 2018

Dr. Chakravarti Selected to Serve on NCI Advisory Board of Scientific Counselors

AC

Arnab Chakravarti, MD of the Ohio State University and co-Chair of the NRG Oncology Brian Tumor Committee, was recently selected to serve a five-year term on the National Cancer Institute (NCI) Advisory Board of Scientific Counselors. In his new role, Dr. Chakravarti will be chairing the review of the NCI Radiation Oncology Program and of the NCI Neuro-Oncology Program in future years.

Dr. Chakravarti’s experience includes research regarding novel biomarkers and uncovering key molecular and genetic mechanisms of treatment resistance in cancer. His team was among the first to report that the dysregulation of PI3K/AKT signaling is associated with radiation resistance in glioblastomas. 
Read more

 

March 30, 2018

Dr. Felix Feng Selected as the New NRG Oncology Genitourinary Cancer Committee Chair 

Felix Feng 7

NRG Oncology has appointed Felix Feng, MD of the University of California at San Francisco as Chair of its Genitourinary Cancer Committee. He will follow Howard M. Sandler, MD, MS, who  dedicated twenty-one years of leadership and direction for the committee.            

Dr. Feng, a nationally and internationally recognized expert in the care of patients with genitourinary malignancies, has helped to initiate several clinical trials which have been among the first to utilize genomic biomarkers to help personalize therapy for prostate cancer patients. He has built a comprehensive research program focused on translating laboratory findings to the clinic to help guide patient care. Read more

 

March 23, 2018
Drs. Bernard Fisher and Norman Wolmark receive Society of Surgical Oncology's 2018 Charles M. Balch, MD Distinguished Service Award. Read more

March 12, 2018

Project Team Member Application – Radium-223

Applicants, please submit the form to the NRG protocol development office by COB Thursday, March 22, 2018. NRG Oncology will submit the application to CTEP by the deadline of March 29, 2018.


March 7, 2018

Bruner

NRG Oncology NCORP PI, Dr. Bruner, Appointed as NCI Global Health 
Working Group Co-Chair

Deborah Watkins Bruner, RN, PhD, FAAN, NRG Oncology’s National Cancer Institute (NCI) National Community Oncology Research Program (NCORP) grant contact primary investigator (PI) and deputy group chair of the organization’s Scientific Publications Committee, was recently appointed as Co-chair of NCI’s Global Health Working Group. In her new role, Dr. Bruner will be reviewing the NCI global portfolio and providing recommendations for the allocation of NCI’s resources. Read more

February 19, 2018

NRG Oncology NCORP Pilot Projects
NRG Oncology NCORP is soliciting PILOT projects for applications focused on NRG NCORP Cancer Prevention and Control (CPC) priorities
that will provide data that will directly lead to future Phase II-III CPC concepts. As put forward in our core grant, CPC priorities for funding are:

  •  Cancer prevention research aimed at identifying and evaluating interventions to reduce the risk and incidence of cancer 
  •  Cancer control research aimed at reducing the incidence and co-morbidity of cancer and its treatment focused on the four symptomatic management  themes: neurotoxicity, cardiotoxicity, lymphedema, and inflammation (including cancer-related fatigue)
  •  Survivorship and palliative care interventions aimed at reducing toxicity and symptom burden, and improving quality of life (QoL)
  •  Cancer disparity research, in collaboration with our Health Disparities Research (HDR) Program, focused on efforts to increase the participation of  minorities and underserved populations in CPC studies
  •  Integral to these priorities, are the establishment of biospecimen repositories for molecular studies. 

For full details read more

NRG Oncology NCORP is soliciting PILOT projects for applications focused on NRG NCORP Cancer Care Delivery Research priorities that will provide data that will directly lead to future CCDR concepts.  As put forward in our core grant, CCDR priorities for funding are:

  • Implementation of guideline-based care
  • Patient-reported outcomes (PROs) 
  • Decision-making tools 
  • Patient navigation 
  • Cardiotoxicity 
  • Survivorship and surveillance

For full details read more

 

February 14, 2018

NRG Oncology Appoints NCORP Investigator, Matthew Hudson, as Cancer Care Delivery Research  Committee Co-Chair

HudsonWeb

NRG Oncology recently appointed Matthew F. Hudson, PhD, MPH as Co-Chair for the organization’s Cancer Care Delivery Research (CCDR) Committee. He joins the present Co-Chair Debra Ritzwoller in the leadership of this committee. Drs. Hudson and Ritzwoller each represent a National Cancer Institute (NCI) Community Oncology Research Program (NCORP) institution. Participating NCORP community sites, like the ones Drs. Hudson and Ritzwoller represent, make cancer research available to larger and more diverse patient populations. Dr. Hudson’s addition to the leadership team may enhance NRG Oncology’s capacity to evolve community-informed research protocols. Read more



February 13, 2018

Aghajanian Appointed as NRG Oncology Gynecologic Cancer Committee Chair

Aghajanian_2017_opt636541261220150055


Carol Aghajanian, MD of Memorial Sloan Kettering Cancer Center (MSK) in New York has been named Chair of NRG Oncology’s Gynecologic Cancer Committee. Dr. Aghajanian’s experience in gynecologic cancer research and her leadership at MSK and within the National Cancer Institute (NCI)’s National Clinical Trials Network (NCTN) will be invaluable to NRG Oncology as the organization pursues its mission of improving the lives of cancer patients through multi-institutional clinical and translational research. She follows the prior NRG Oncology Gynecologic Cancer Committee Chair, Robert S. Mannel, MD, who was elected as an NRG Oncology Group Chair in 2017. Read more

 


February 1, 2018

NRG Oncology Appoints Kati Stoermer for New Executive Director Role 

Stoermer636530970992044892

NRG Oncology, one of the five funded network groups within the National Cancer Institute (NCI)’s National Clinical Trials Network (NCTN), has appointed Kati Stoermer as the organization’s Executive Director. In this new role, Stoermer will be providing oversight and management of the NRG Oncology operational activities coordinated by staff located in Philadelphia and Pittsburgh. She will also be coordinating with the organization’s Statistical and Data Management Center and the group’s Biospecimen Bank. Read more

 

 

NRG Oncology, one of the five funded network groups within the National Cancer Institute (NCI)’s National Clinical Trials Network (NCTN), has appointed Kati Stoermer as the organization’s Executive Director. In this new role, Stoermer will be providing oversight and management of the NRG Oncology operational activities coordinated by staff located in Philadelphia and Pittsburgh. She will also be coordinating with the organization’s Statistical and Data Management Center and the group’s Biospecimen Bank. Read more. 
NRG Oncology, one of the five funded network groups within the National Cancer Institute (NCI)’s National Clinical Trials Network (NCTN), has appointed Kati Stoermer as the organization’s Executive Director. In this new role, Stoermer will be providing oversight and management of the NRG Oncology operational activities coordinated by staff located in Philadelphia and Pittsburgh. She will also be coordinating with the organization’s Statistical and Data Management Center and the group’s Biospecimen Bank. Read more. 
NRG Oncology, one of the five funded network groups within the National Cancer Institute (NCI)’s National Clinical Trials Network (NCTN), has appointed Kati Stoermer as the organization’s Executive Director. In this new role, Stoermer will be providing oversight and management of the NRG Oncology operational activities coordinated by staff located in Philadelphia and Pittsburgh. She will also be coordinating with the organization’s Statistical and Data Management Center and the group’s Biospecimen Bank. Read more. 
Copyright 2018 by NRG Oncology